Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension

C. Farsang, M. Peter, E Andrew Balas, J. Feher

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by α1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K probably may not be mediated by these mechanisms.

Original languageEnglish (US)
JournalJournal of Cardiovascular Pharmacology
Volume10
Issue numberSUPPL. 12
StatePublished - Dec 1 1987

Fingerprint

Hydrochlorothiazide
Prazosin
Uric Acid
Glucose
HDL Cholesterol
Triglycerides
Blood Pressure
LDL Cholesterol
Adrenergic Receptors
Heart Rate
Cholesterol
Essential Hypertension
Lipids
Therapeutics
Serum
oxidized low density lipoprotein

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. / Farsang, C.; Peter, M.; Balas, E Andrew; Feher, J.

In: Journal of Cardiovascular Pharmacology, Vol. 10, No. SUPPL. 12, 01.12.1987.

Research output: Contribution to journalArticle

@article{833c3056e72f49a5a350cadd181a2ee0,
title = "Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension",
abstract = "Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by α1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K probably may not be mediated by these mechanisms.",
author = "C. Farsang and M. Peter and Balas, {E Andrew} and J. Feher",
year = "1987",
month = "12",
day = "1",
language = "English (US)",
volume = "10",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 12",

}

TY - JOUR

T1 - Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension

AU - Farsang, C.

AU - Peter, M.

AU - Balas, E Andrew

AU - Feher, J.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by α1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K probably may not be mediated by these mechanisms.

AB - Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by α1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K probably may not be mediated by these mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0023613804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023613804&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 12

ER -